ライフサイエンスコーパス: lung transplant

1 aneous coronary intervention; or heart/heart-lung transplant).

2 ry T, NK, and NKT-like lymphocytes following lung transplant.

3 tions and no effective therapies, aside from lung transplant.

4 ended intensive care including the option of lung transplant.

5 or clinical outcomes, particularly following lung transplant.

6 esource use during index hospitalization for lung transplant.

7 increased risk of delisting or death before lung transplant.

8 r and how lymphatic anastomosis occurs after lung transplant.

9 dity and mortality among patients undergoing lung transplant.

10 ad positive donor BAL testing at the time of lung transplant.

11 is common during the initial 3 months after lung transplant.

12 y and is useful for graft monitoring after a lung transplant.

13 nt presenting with a lung mass 3 years after lung transplant.

14 esent at intermediate frequencies before the lung transplants.

15 d early improvement in PFR and proportion of lungs transplanted.

16 urvival probability between LLT and isolated lung transplant (1 y, 89.5% vs 86.7%; 5 y, 67.0% vs 64.6

17 70-year-old man who underwent a single right lung transplant 103 days after transcatheter aortic valv

18 There was no difference in the rate of lungs transplanted (19% in both groups, P = 0.97) althou

19 t; 58 (17.6%), heart transplant; 54 (16.4%), lung transplant; 34 (10.3%), liver transplant; and 6 (1.

20 was a 66-year-old man who underwent a double lung transplant 56 days after transcatheter aortic valve

21 cipient serum ferritin >500 ug/L), and for a lung transplant 6.3 (Burkholderia cepacia complex infect

22 years; heart transplant, 269,715 life-years; lung transplant, 64,575 life-years; pancreas-kidney tran

23 e screening tests in donor and candidate pre-lung transplant, 8.3% (n = 5) of recipients had positive

24 neumonia (aHR, 1.8; 95% CI, 1.3-2.3), single lung transplant (aHR, 1.3; 95% CI, 1.0-1.7), and idiopat

25 cause of early morbidity and mortality after lung transplant and is characterized by severe hypoxemia

26 change in mean total hospital charges among lung transplant and other solid-organ transplant recipie

27 sed in proinflammatory lymphocytes following lung transplant and that treatment with SIRT1 activators

28 Rates for death or double-lung transplant and the composite rates for death, doubl

29 al of 44 patients were enrolled: 36 received lung transplants and 8 received heart transplants.

30 e might prove highly valuable for evaluating lung transplants and lung resections, and could improve

31 o effective treatments for ACDMPV other than lung transplant, and new therapeutic approaches are urge

32 CMV D+/R- serostatus, lung transplant, and treatment phase viral kinetics were

33 Six patients underwent lung transplant, and two died on the waiting list after

34 Every year, thousands of heart and lung transplants are performed worldwide.

35 ur, but also introduces the mouse orthotopic lung transplant as a model for studying the immunobiolog

36 tion (100% at 40 HAU and 60% healthy and 61% lung transplant at 160 HAU; P = 1.0; chi-square).

37 plant Outcomes Group who underwent bilateral lung transplant at our institution between 2004 and 2014

38 cohort study including recipients of primary lung transplants between 2008 and 2012.

39 rvival were estimated among adults receiving lung transplants between June 2010 and June 2015 based o

40 rejection is emerging in kidney, heart, and lung transplant biopsies and could offer insights for li

41 dated their use in kidney, liver, heart, and lung transplant biopsies.

42 zithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

43 ortic valve replacement may favorably impact lung transplant candidacy for patients with end-stage lu

44 n response to a lawsuit from a New York City lung transplant candidate, an emergency change to the lu

45 Frailty is prevalent among lung transplant candidates and is independently associat

46 Coronary artery disease (CAD) is common in lung transplant candidates and may require revasculariza

47 Many lung transplant candidates and recipients are older and

48 tionship between pretransplant opioid use in lung transplant candidates and retransplant-free surviva

49 The prevalence of anti-HLA antibodies in lung transplant candidates and their impact on waitlist

50 These data show that one third of lung transplant candidates do not survive 1 year after t

51 We performed an ecologic study of 12 187 lung transplant candidates listed at 56 U.S. lung transp

52 The impact of opioid use in lung transplant candidates on posttransplant outcomes is

53 it-list and post-transplant mortality for CF lung transplant candidates using a novel database and to

54 its, and both types of frailty are common in lung transplant candidates.

55 research on assessment of elderly and frail lung transplant candidates.

56 tance is an important component of access to lung transplant care.

57 All lung transplant cases between January 2000 and July 2013

58 s typically considered the primary metric of lung transplant center performance in the United States.

59 We designed a novel lung transplant center performance metric that incorpora

60 6 and 2012 at our institution, a high-volume lung transplant center.

61 lung transplant candidates listed at 56 U.S. lung transplant centers between 2006 and 2012.

62 Although most lung transplant centers use antifungal prophylaxis, cons

63 inal organs by means of EVLP with a standard lung transplant cohort through a multicenter open trial.

64 ncidence of AR in a contemporary multicenter lung transplant cohort undergoing consistent biopsy samp

65 ransplant year in a present-day, five-center lung transplant cohort.Methods: We analyzed prospective

66 sortium comprising heart, kidney, liver, and lung transplant cohorts.

67 r liver transplants and 3.07, 1.96-4.81, for lung transplants, compared with kidney transplants), and

68 Five out of six patients (83.3%) receiving a lung transplant could be discharged from hospital.

69 ymphatic connections are reestablished after lung transplant, despite evidence suggesting that this d

70 Endothelial glycocalyx breakdown occurs in lung transplant donors and recipients and predicts organ

71 median, 29.6 y) received bilateral deceased lung transplants for pulmonary chronic GVHD between 2002

72 ithout HCV infection who received a heart or lung transplant from donors with hepatitis C viremia, tr

73 ts than in a cohort of patients who received lung transplants from donors who did not have HCV infect

74 Lungs transplanted from rotated donors had better immedi

75 ry remains a major contributor to early post-lung transplant graft dysfunction and mortality.

76 ations, an intervention was necessary in the lung transplant group compared to 32% (n = 79/245) in th

77 Double-lung transplants had a time-varying association with gra

78 lammation; however, SIRT1 activity following lung transplant has not been studied.

79 Traditionally, most lung transplants have been performed in older children a

80 range of patient travel distances to reach a lung transplant hospital in the United States.

81 95% confidence interval [CI], 0.89-0.97) and lung transplant (HR, 0.90; 95% CI, 0.84-0.97) but not ki

82 erience with constrictive pericarditis after lung transplant in an effort to investigate the cause an

83 to concomitant aortic valve replacement and lung transplant in elderly patients.

84 with experience of performing more than 170 lung transplants in the first 5 years of the lung alloca

85 All recipients of kidney, liver, heart, and lung transplants in the United Kingdom between 1987 and

86 We present a cohort study of lung transplants in the United States between January 1,

87 er case of synchronous CRC arising in a post-lung transplant individual with CF within the recommende

88 tween C57BL/6J and DBA/2J) (Haplotype H2b/d) lungs transplanted into DBA/2J (H2d) recipients were ide

89 In liver and lung transplant, longer time between listing and transpl

90 We investigated whether deceased-donor lung transplant (LT) rates differed substantially betwee

91 miR-16 and miR-195 levels were also noted in lung transplant (LTx) patients with DSA compared with LT

92 ated hemoglobin [HbA1c]) and survival in all lung transplant (LTx) recipients and those with either p

93 humidified high flow nasal cannula (HFNC) in lung transplant (LTx) recipients readmitted to intensive

94 Weight gain is commonly seen in lung transplant (LTx) recipients.

95 In an in vivo mouse orthotopic lung transplant model of BOS, antagonism of the LPA rece

96 ablation of lymphatic endothelial cells in a lung transplant model revealeded that loss of lymphatic

97 tibility complex-mismatched mouse orthotopic lung transplant model, we investigated a conditioning re

98 ogical and functional outcomes in the murine lung transplant model.

99 tibility complex-mismatch murine cardiac and lung transplant models, and in a humanized skin transpla

100 accelerates tissue damage and increases post-lung transplant mortality in cystic fibrosis patients.

101 the etiology, with some forms progressing to lung transplant or death.

102 ) but did not differentially increase single lung transplants or pretransplant ECMO utilization.

103 efined as time to death, acute exacerbation, lung transplant, or decrease in forced vital capacity (F

104 mary outcome was time to death (all causes), lung transplant, or first nonelective hospital admission

105 nt and the composite rates for death, double-lung transplant, or restenosis at 36 months were 5% and

106 pportunities to ultimately improve long-term lung transplant outcome.

107 objective of this study was to examine early lung transplant outcomes following EVLP using a large na

108 iation study of the multicenter, prospective Lung Transplant Outcomes Group cohort.

109 etrospective cohort study of patients in the Lung Transplant Outcomes Group who underwent bilateral l

110 patient travel distance was associated with lung transplant outcomes.

111 to further assess the impact of EVLP on post-lung transplant outcomes.

112 treatment phase viral kinetics (P = 0.005), lung transplant (P = 0.002), CMV donor (D)+/recipient (R

113 P = 1.0) and at 160 HAU (24% healthy and 36% lung transplant; P = 0.40) were observed.

114 tection rates at 40 HAU (95% healthy and 97% lung transplant; P = 1.0) and at 160 HAU (24% healthy an

115 A lung transplant patient with invasive aspergillosis (IA)

116 use of aerosolized voriconazole for IA in a lung transplant patient.

117 ells from patients with BOS (n = 10), stable lung transplant patients (n = 11), and healthy aged-matc

118 cted from patients with BOS (n = 10), stable lung transplant patients (n = 18), and healthy aged-matc

119 lected from patients with BOS (n=10), stable lung transplant patients (n=18) and healthy aged-matched

120 uggest that MMF is present in the airways of lung transplant patients and might affect the structural

121 lence of PTMS but also identifies kidney and lung transplant patients as being at a particularly high

122 Thirty-two lung transplant patients developed mild (16%), moderate

123 ected in the bronchoalveolar lavage fluid of lung transplant patients diagnosed with IA that received

124 e center, retrospective case series study of lung transplant patients followed by the Columbia Lung T

125 bronchoalveolar lavage fluid and plasma from lung transplant patients with and without PGD.

126 Thirty-six of 71 (51%) phase 1 cases were lung transplant patients with positive respiratory cultu

127 For lung transplant patients, mortality after listing was hi

128 kidney allotransplantation patients and six lung transplant patients.

129 r immunization in 25 healthy controls and 54 lung transplant patients.

130 ne should continue to be a high priority for lung transplant patients.

131 orm for the development of new therapies for lung transplant patients.

132 rome seriously reduces long-term survival of lung transplanted patients.

133 Solitary kidney, liver, heart, and lung transplants performed between January 1, 2011, and

134 has the potential to increase the number of lung transplants performed worldwide.

135 arly diagnosis of IFI is questionable in the lung transplant population.

136 In kidney, liver, and lung transplant, posttransplant evaluations at listing h

137 transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS-CoV

138 a, Celsior solution was used in our clinical lung transplant program.

139 The majority of heart and lung transplant providers in our study sample supports t

140 nt, voluntary, web-based survey of heart and lung transplant providers to assess current practice pat

141 The treatment is complex, but lung transplant provides substantial survival benefit an

142 ifferences in eventual outcomes in liver and lung transplant, providing useful information to patient

143 luation, we retained 60 items comprising the Lung Transplant Quality of Life (LT-QOL) Survey.

144 Longitudinal posttransplant monitoring of a lung transplant recipient (A2, CMV seropositive) who rec

145 Two temporal lung transplant recipient cohorts identified by joinpoin

146 omonas isolates and airway samples from a CF-lung transplant recipient during two years, and followed

147 rst donor-derived C. auris transmission in a lung transplant recipient.

148 cipient, 1 heart transplant recipient, and 1 lung transplant recipient.

149 Thirty-eight lung transplant recipients (38.8%) developed CLAD, in a

150 thod to sequencing of cfDNA in the plasma of lung transplant recipients (40 samples, six patients).

151 ssociated with treatment among the colonized lung transplant recipients (8/12 [67%] vs 3/25 [12%] who

152 s not associated with increased mortality in lung transplant recipients (9/43 [20.9%] in infected die

153 n (CLAD) is the major outcome limitation for lung transplant recipients (LTR) after the first year, a

154 spiratory syncytial virus (RSV) infection in lung transplant recipients (LTRs) causes mortality rates

155 ACR) in the bronchoalveolar lavage (BAL) of lung transplant recipients (LTRs) to determine the assoc

156 In a randomized controlled trial, lung transplant recipients (LTRs) using a mobile health

157 In lung transplant recipients (LTRs), human cytomegalovirus

158 nificant cause of morbidity and mortality in lung transplant recipients (LTRs).

159 techniques in a large contemporary cohort of lung transplant recipients (LTRs).

160 oietic cell transplantation, particularly in lung transplant recipients (LTRs).

161 solid organ transplantation, particularly in lung transplant recipients (LTRs).

162 ovirus (HCMV) may cause severe infections in lung transplant recipients (LTRs).

163 with development of AR and BOS in pediatric lung transplant recipients (LTxR).

164 V) replication and disease commonly occur in lung transplant recipients after stopping anti-CMV proph

165 center retrospective cohort study of primary lung transplant recipients and examined risk factors for

166 MV infection in 23 (donor+/recipient-; D+R-) lung transplant recipients and found rapid induction of

167 y artery disease has a high prevalence among lung transplant recipients and has historically been a c

168 onchiolitis [LB]) distribution, is common in lung transplant recipients and increases the risk for ch

169 ains a serious postoperative complication in lung transplant recipients and is associated with signif

170 cer-specific survival were noted between non-lung transplant recipients and nontransplant patients.

171 he blood and bronchoalveolar lavage (BAL) of lung transplant recipients and stratified recipients bas

172 Lung transplant recipients are among those with the high

173 rvival difference between single- and double-lung transplant recipients at 5 years.

174 Lung transplant recipients at our hospital had high rate

175 ral blood mononuclear cell specimens from 39 lung transplant recipients at the time of transplantatio

176 dy was to evaluate survival to discharge for lung transplant recipients based on length of stay (LOS)

177 n the lung transplant waiting list and 6,110 lung transplant recipients between 2011 and 2014, compri

178 t.Methods: We enrolled 156 of the 209 double lung transplant recipients between December 2017 and Mar

179 specimens from symptomatic and asymptomatic lung transplant recipients both by culture (using a clin

180 d in bronchoalveolar lavage (BAL) fluid from lung transplant recipients by enzyme-linked immunosorben

181 usly monitors for rejection and infection in lung transplant recipients by sequencing of cell-free DN

182 Lung transplant recipients commonly develop invasive fun

183 alysis of transbronchial biopsies from human lung transplant recipients demonstrated an association b

184 Eight of 807 lung transplant recipients developed hyperammonemia synd

185 In total, 156 of 815 lung transplant recipients developed IFIs (prevalence ra

186 and effective in treating CMV-infections in lung transplant recipients failing on currently availabl

187 similar increase in NKG2C NK cells occurs in lung transplant recipients following CMV reactivation in

188 In the cohort of 1528 lung transplant recipients from 12 transplant centers, d

189 of M. hominis infections were identified in lung transplant recipients from the same thoracic intens

190 ) was increased in bronchoalveolar lavage of lung transplant recipients growing P. aeruginosa (11.5 [

191 Lung transplant recipients have an increased risk for in

192 ncreased total hospital charges occurred for lung transplant recipients in 2005, corresponding to LAS

193 is was a retrospective cohort study of adult lung transplant recipients in the Scientific Registry of

194 scRNA-seq of BAL cells from lung transplant recipients indicates that after transpla

195 The average age of lung transplant recipients is increasing, and the mix of

196 chronic lung allograft dysfunction (CLAD) in lung transplant recipients is still controversial.

197 ion, but the optimal vaccination schedule in lung transplant recipients is unknown.

198 Thus, immunosuppressive strategies for lung transplant recipients need to be tailored based on

199 Three lung transplant recipients presented with invasive M. ho

200 PRM is a novel imaging tool for lung transplant recipients presenting with spirometric d

201 Two lung transplant recipients receiving immunosuppressive t

202 Acute cellular rejection (ACR) in lung transplant recipients requires demonstration of per

203 lar clinical picture is seen, teams managing lung transplant recipients should be aware of this poten

204 efits of voriconazole use when prescribed to lung transplant recipients should be carefully weighed v

205 rospective study was performed including all lung transplant recipients suffering from bronchiolitis

206 This pilot study in lung transplant recipients suggests that supplementing p

207 Lung transplant recipients undergoing diagnostic broncho

208 e investigated a single-center cohort of 340 lung transplant recipients undergoing transplant during

209 We assembled a large cohort of lung transplant recipients using 2004 to 2010 Internatio

210 In an observational pilot study, 28 lung transplant recipients were enrolled in a novel post

211 Nine hundred lung transplant recipients were included.

212 Lung transplant recipients were more likely to seroconve

213 ngitudinally in bronchoalveolar lavages from lung transplant recipients who developed bronchiolitis o

214 m preliminary survey was administered to 201 lung transplant recipients with a mean age of 57.9 (+/-1

215 nd serum HA and the HA immobilizer LYVE-1 in lung transplant recipients with and without acute cellul

216 We reviewed the survival of lung transplant recipients with CAD requiring surgical i

217 Lung transplant recipients with CARVs in the lower respi

218 We report a series of 4 lung transplant recipients with CMV-infection and treatm

219 Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6

220 3, and -4 in bronchoalveolar lavage (BAL) of lung transplant recipients with good outcome and BOS usi

221 se (PRM(PD)) were compared between bilateral lung transplant recipients with irreversible spirometric

222 Three of 6 lung transplant recipients with NTM disease died compare

223 The care of lung transplant recipients with prolonged index hospital

224 Adult lung transplant recipients with small chests have tradit

225 We investigated the TTV-DNA levels in 34 lung transplant recipients within their first year after

226 imilarly good early survival as contemporary lung transplant recipients without early DSA.

227 Among lung transplant recipients, "bronchiolitis obliterans sy

228 Among 251 lung transplant recipients, 50 developed PGD Grade 3.

229 pients, 190 liver transplant recipients, 102 lung transplant recipients, 79 heart transplant recipien

230 logy-oncology population and up to 23% among lung transplant recipients, and have a rate of 7.1-8.3 c

231 ore commonly than early-onset CMV disease in lung transplant recipients, and is associated with an in

232 elopment of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for

233 factors for common fungal infections seen in lung transplant recipients, evaluates the clinical effic

234 In the largest national series of EVLP lung transplant recipients, EVLP is associated with earl

235 We studied 328 lung transplant recipients, from January 2006 to July 20

236 In lung transplant recipients, immunosuppressive medication

237 In bronchoalveolar lavage fluid from human lung transplant recipients, NETs were more abundant in p

238 es from healthy subjects, HIV+ subjects, and lung transplant recipients, providing a gradient of incr

239 can be so difficult to effectively treat in lung transplant recipients, the development of an animal

240 -derived CD4 T cells in 21 consecutive human lung transplant recipients, with 3 patterns of chimerism

241 ntially bronchiolitis obliterans syndrome in lung transplant recipients, with a greater propensity fo

242 The 84 remaining items were field tested in lung transplant recipients.

243 F-FDG PET/CT scan, in comparison with stable lung transplant recipients.

244 mportant opportunistic pathogen in high-risk lung transplant recipients.

245 may be a marker of allograft dysfunction in lung transplant recipients.

246 itional tool to monitor immunosuppression in lung transplant recipients.

247 the impact of pretransplant sensitization on lung transplant recipients.

248 cipients, and Pseudomonas aeruginosa (9%) in lung transplant recipients.

249 ed with increased risk of SCC of the skin in lung transplant recipients.

250 rm immunological follow up of a cohort of 55 lung transplant recipients.

251 is predictive of subsequent mortality among lung transplant recipients.

252 the association of NTM with mortality among lung transplant recipients.

253 certain the optimal prophylactic strategy in lung transplant recipients.

254 ic mitochondrial cfDNA in the circulation of lung transplant recipients.

255 ased mortality compared with colonization in lung transplant recipients.

256 ts, NTM were most frequently identified from lung transplant recipients.

257 t or treat DQ-dnDSA may improve outcomes for lung transplant recipients.

258 ls, now describes the use mTOR inhibitors in lung transplant recipients.

259 scontinuation rates are particularly high in lung transplant recipients.

260 severe illness and a high mortality rate in lung transplant recipients.

261 nic graft failure and long-term mortality in lung transplant recipients.

262 commonly than early-onset CMV disease among lung transplant recipients.

263 FVC values were studied among 205 bilateral lung transplant recipients.

264 r the development of cutaneous malignancy in lung transplant recipients.

265 ked to fatal hyperammonemia syndrome (HS) in lung transplant recipients.

266 may be involved in regulating lung injury in lung transplant recipients.

267 lammatory cells isolated from sex-mismatched lung transplant recipients.

268 here are limited data describing COVID-19 in lung transplant recipients.

269 Patients were adult bilateral lung transplant recipients.

270 associated with ACR or CLAD-free survival in lung transplant recipients.

271 nt that characterizes and quantifies HRQL in lung transplant recipients.

272 omains previously identified as important by lung transplant recipients.

273 three patients (86%) with NTM infection were lung transplant recipients; 18 of 43 (41.8%) were treate

274 Overall, 98 patients (67 bilateral lung transplant recipients; 63.3% male; mean age, 49.9 y

275 t was indicated occurred in the HCV-infected lung-transplant recipients than in a cohort of patients

276 We investigated the effect of LAS trends on lung transplant-related costs, healthcare utilization, a

277 We aimed to develop a comprehensive lung transplant-specific instrument to address this shor

278 Lung transplant survival is limited by obliterative bron

279 tance was significantly associated with post lung transplant survival.

280 and without definitive treatment other than lung transplant to prolong life.

281 During lung transplant tolerance, Foxp3+ cells accumulate in te

282 pportive care would assist hematopoietic and lung transplant units in optimizing resource allocation

283 An orthotopic murine model of lung transplant using lymphatic reporter mice and whole

284 ion between frailty and disability using the Lung Transplant Valued Life Activities disability scale.

285 ic stenosis who were successfully bridged to lung transplant via transcatheter aortic valve replaceme

286 ty-five centers were classified according to lung transplant volume in 2005-2010, with 8,228 adults (

287 retrospective, population-based study of all lung transplant wait-list candidates aged 12 years or ol

288 ber 31, 2014, included 9,043 patients on the lung transplant waiting list and 6,110 lung transplant r

289 cohort study of 13,346 adults placed on the lung transplant waiting list in the United States betwee

290 ients was 65 years, and the median time from lung transplant was 5.6 years.

291 iation was present for heart transplant, and lung transplant was associated with higher mortality.

292 Donor-derived Ureaplasma spp in lung transplant was associated with HS.

293 An adverse effect of ECMO at the time of lung transplant was evident in low-volume centers but ab

294 60 patients who underwent lung transplant were included.

295 helial cells (PBECs), and PBECs derived post-lung transplant were transfected with miR-200b-3p mimics

296 d for with propensity score analysis, double-lung transplants were associated with better graft survi

297 From January 2003 to August 2009, 593 lung transplants were performed at our institution.

298 Forty patients (4.1%) underwent lung transplant with 50% postoperative in-hospital morta

299 railty is common among patients referred for lung transplant with a diagnosis of ILD and is associate

300 e amenable to surgical management, combining lung transplant with surgical valve repair is rarely don